- Q4 Revenue Growth: Net Vysovec revenue reached $107.1 million in Q4 2025, with total sales since launch exceeding $730 million.
- Global Expansion: Distributor agreements now cover over 20 countries, aiming to expand to 40 by 2026, with strong momentum in Europe, Japan, and Germany.
- Operating Profitability: Net income for Q4 was $51.4 million ($1.70 diluted EPS), driven by 94% gross margin and a one-time tax benefit from U.S. legislation.
- Pipeline Progress: Breakthrough data on KB407 for CFTR protein delivery reported, with registrational trial design discussions underway with FDA and CFFTDN.
- Cost Management: Operating expenses rose to $13.8 million (Q4) due to global launches, but 2026 non-GAAP R&D/SG&A guidance remains capped at $175–195 million.
Revenue Growth Drivers
Krish S. Krishnan, chairman and CEO, highlighted that geographic expansion is a major driver of revenue growth, with accelerating demand in the US, Europe, and Japan. The company has seen reimbursement approval acceleration for three consecutive quarters, with over 660 prescribers since launch, and added over 50 new prescribers in Q4. The global Vizurevac launch continues to progress well, with over 90 TED patients prescribed in Germany, France, and Japan combined.
Pipeline Advancements
The company is making rapid progress on its rare disease pipeline, generating breakthrough clinical data, and moving quickly towards multiple registrational data readouts later this year. Suma M. Krishnan mentioned the successful delivery and expression of full-length wild-type CFTR protein following KB407 administration to the lung of patients with CF. The company is confident in its enrollment projections for the ocular and NK programs and expects to complete enrollment by the end of the year.
Valuation Metrics
With a P/E Ratio of 41.9 and an EV/EBITDA of 45.87, the market is pricing in significant growth expectations. The company's ROE is 18.15%, indicating a strong return on equity. Analysts estimate next year's revenue growth at 34.0%, which is in line with the company's historical growth trajectory. The stock's current valuation multiples suggest that the market is optimistic about the company's future prospects, and the recent earnings beat is likely to further boost investor confidence.
Future Outlook
Krish S. Krishnan discussed the company's plans for 2026, with a focus on geographic expansion and pipeline advancements. The company expects to reach a pricing agreement with Germany in the second half of 2026 and with France in the first half of 2027. The company is not intending to use its cash to in-license or buy third-party technology or companies at the moment but may explore stock buyback options in the future.